A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration—the FALCON study

BACKGROUND: Treatment initiation with brolucizumab, a new potent anti-vascular endothelial growth factor (VEGF) agent, is typically performed with three monthly injections (loading dose) and has been well studied in treatment-naïve patients. However, no clinical data are available yet on whether or...

Descripción completa

Detalles Bibliográficos
Autores principales: Holz, F. G., Schmitz-Valckenberg, Steffen, Wolf, A., Agostini, H., Lorenz, K., Pielen, A., Feltgen, N., Guthoff, R., Quiering, C., Clemens, A., Jaeger, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Medical Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325853/
https://www.ncbi.nlm.nih.gov/pubmed/35188581
http://dx.doi.org/10.1007/s00417-022-05591-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325853/
https://www.ncbi.nlm.nih.gov/pubmed/35188581
http://dx.doi.org/10.1007/s00417-022-05591-z

Ejemplares similares